Project Grant R21AI183094
Award Date
5/28/24
Completion Date
3/31/26
Dollars Obligated
$672K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Tampa, FL 33612, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID), through the Allergy and Infectious Diseases Research program (CFDA 93.855), has awarded a $300,000 Project Grant to Biotherapeutics, Inc., a biotech company located in Blacksburg, Virginia. The grant aims to accelerate the development of Biotherapeutics' novel, oral, first-in-class immunoregulatory therapeutic for the treatment of Clostridioides difficile infection (CDI). The specific objectives of this SBIR Phase I grant are to:...
This $511,553 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of a novel probiotic yeast-based immunotherapy to prevent the transmission of Clostridioides difficile infections (CDI). The University of Maryland, Baltimore will utilize engineered probiotic yeast to deliver neutralizing antibodies against the C. difficile surface protein CWP84, which is...
This $894,552 project grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases Allergy and Infectious Diseases Research program (CFDA 93.855) will fund research at the University of Nevada, Las Vegas to probe the effect of a high-fat/high-protein diet on Clostridioides difficile infection. Specifically, the researchers will examine how such a diet impacts inflammation, intestinal permeability, and the gut microbiome before and after antibiotic...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $754,446 to the University of Tennessee Health Science Center to develop novel microbiome-sparing antibacterial treatments for Clostridioides difficile infection (CDI). The key objectives are to: 1) Optimize and improve the potency of the team's lead inhibitor series targeting the CDI enzyme FabK; 2) Identify and characterize new chemical...
This $650,000 Project Grant awarded by the National Center for Advancing Translational Sciences (NCATS), under CFDA Program 93.350, supports research and development for a next generation probiotics-based platform technology to enable oral delivery of peptide and protein therapeutics. Specifically, the project aims to (1) develop an antibiotic-resistance-free expression system for stable, high-level production of therapeutic peptides in Lactobacillus probiotic strains, (2) create inducible...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $261,492 Project Grant (R21AI188339) to the Trustees of Tufts College, doing business as Tufts University School of Medicine, to conduct research on the epigenetic regulation of sporulation in Clostridioides difficile, a major nosocomial pathogen. The research aims to elucidate the impact of DNA methylation on C. difficile physiology, which could facilitate the development of new therapeutics. The project builds on...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to advance the development and manufacturing of defined live biotherapeutic products (LBPs) for infectious and inflammatory diseases. The $1,255,725 award, with a performance period from February 1, 2025 to January 31, 2029, will support the following key objectives: 1) Developing a...
This federal Project Grant award of $506,000.00, provided by the National Center for Complementary and Integrative Health (NCCIH) under the Research and Training in Complementary and Integrative Health program (CFDA 93.213), aims to develop recombinant peptidoglycan hydrolase therapeutics to promote intestinal barrier function and protect against enteric pathogens. The award, granted to the Scripps Research Institute in La Jolla, CA, will fund research to evaluate the activity of these...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $171,254 to the Nimml Institute Inc., a 501(c)(3) non-profit research organization, to investigate novel immunometabolic mechanisms that can interfere with the toxin internalization and processing of Clostridioides difficile infection (CDI). The key objectives of this 2-year research project are to: 1)...
The Project Grant award for "SPORE GERMINATION PATHWAY IN CLOSTRIDIOIDES DIFFICILE AND ITS PHARMACOLOGICAL INTERVENTION" was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The $1,541,024 award aims to elucidate the spore germination pathway of the bacterium Clostridioides difficile, which is a leading cause of deadly antibiotic-associated infections. The research seeks to understand...